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HIV up-regulates cell-surface expression
of specific ligands for the activating
NKG2D receptor, including ULBP-1, -2,
and -3, but not MICA or MICB, in infected
cells both in vitro and in vivo. However,
the viral factor(s) involved in NKG2D li-
gand expression still remains undefined.
HIV-1 Vpr activates the DNA damage/
stress-sensing ATR kinase and promotes
G2 cell-cycle arrest, conditions known to
up-regulate NKG2D ligands. We report
here that HIV-1 selectively induces cell-
surface expression of ULBP-2 in primary
CD4 T lymphocytes by a process that is
Vpr dependent. Importantly, Vpr enhanced
the susceptibility of HIV-1–infected cells
to NK cell–mediated killing. Strikingly, Vpr
alone was sufficient to up-regulate expres-
sion of all NKG2D ligands and thus pro-
moted efficient NKG2D-dependent
NK cell–mediated killing. Delivery of
virion-associated Vpr via defective HIV-1
particles induced analogous biologic ef-
fects in noninfected target cells, suggest-
ing that Vpr may act similarly beyond
infected cells. All these activities relied
on Vpr ability to activate the ATR-
mediated DNA damage/stress checkpoint.
Overall, these results indicate that Vpr is
a key determinant responsible for HIV-1–
induced up-regulation of NKG2D ligands
and further suggest an immunomodula-
tory role for Vpr that may not only contrib-
ute to HIV-1–induced CD4 T-lymphocyte
depletion but may also take part in HIV-1–
induced NK-cell dysfunction. (Blood.
2010;115:1354-1363)
Introduction
HIV-1 has evolved multiple strategies to induce a persistent
infection in hosts. Several of these strategies rely on an array of
virally encoded accessory proteins, including Vif, Vpr, Vpu, and
Nef, which collectively appear to manipulate host cell biology as a
means to ensure a favorable cellular state for viral replication,
transmission, dissemination, and immune evasion.1 Vpr (Viral
protein R), one of these accessory proteins, is a 96-amino acid
protein that is expressed at the late stage of the virus life cycle but is
present during the early steps of infection because it is packaged
into viral particles via an interaction with the p6 domain of Gag.2,3
The protein also exists in an extracellular form because it can be
detected in the serum and cerebrospinal fluid of HIV-1–infected
persons.4 One of the main biologic activities of Vpr is the induction
of a G2 cell-cycle arrest.5-7 Interestingly, soluble and virion-
associated Vpr molecules also display cytostatic activities,8-10
raising the possibility that Vpr may exert this biologic activity
beyond infected cells. The observations that Vpr-mediated G2
cell-cycle arrest is well conserved among the primate lentivi-
ruses11,12 and that HIV-1–infected persons display an abnormal
number of cells accumulating in the G2 phase13 suggest that this
activity probably plays an important role in HIV-1 pathogenesis.
Although its functional significance is still not well understood, its
mechanism has recently been in part elucidated. Vpr appears to
induce a G2 cell-cycle arrest by mimicking a DNA stress/damage
checkpoint arrest initiated by the DNA damage-sensing protein
kinase ATR (ataxia telangiectasia-mutated and Rad3-related).14
The proximal events that trigger G2 cell-cycle arrest were recently
found to rely on the engagement by Vpr of a cullin-RING E3
ubiquitin (Ub) ligase complex, DDB1-CUL4A (VprBP). The
recruitment of the complex would lead to polyubiquitination and
proteasomal degradation of a yet unknown cellular protein(s)
resulting ultimately in activation of ATR signaling pathway.15-21
DNA stress/damage checkpoint pathways initiated by ATM
(ataxia telangiectasia-mutated) or ATR protein kinases are essential
to the maintenance of genomic integrity and stability, but interest-
ingly, recent findings suggest that they are also involved in innate
immune surveillance. Indeed, it has recently been demonstrated
that genotoxic agents up-regulate expression of ligands of the
activating natural killer group 2, member D (NKG2D) receptor
through the activation of ATM and ATR and enhance destruction of
treated cells by natural killer (NK) cells.22 NKG2D is a potent
activating receptor expressed not only on NK cells, but also on 
T cells, CD8 T cells and a small subset of CD4 T cells.23,24
Human NKG2D ligands consist of 2 classes of MHC-I-like
molecules: MHC-1-related chains (MIC) and human cytomegalovi-
rus UL16 binding proteins (ULBP), which are generally poorly
expressed by normal cells and up-regulated on virus-infected,
tumor, and stressed cells.23,24 Activating signals delivered through
the NKG2D receptor expressed by NK and T cells induce the
killing of pathogen-infected cells as well as cancer cells both in
vitro and in vivo.23,24
Because HIV-1 infection of primary CD4 T lymphocytes was
recently reported to increase cell-surface expression of specific
NKG2D ligands both in vitro and in vivo,25-27 we investigated in
the present study whether the HIV-1 Vpr accessory protein could
regulate the expression of ligands for the activating NKG2D
receptor and modulate NK-cell cytotoxic responses. Herein, we
provide evidence that Vpr, in the absence of any other viral gene
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products, is sufficient to up-regulate cell-surface expression of
MICA, MICB, and ULBP-1, -2, and -3, with the strongest effect
observed with ULBP-2. We also show that Vpr-mediated up-
regulation of ULBP-2 is dependent on the ability of Vpr to engage
the DDB1-CUL4A (VprBP) E3 Ub ligase and to activate the
ATR-mediated DNA damage/stress checkpoint. Importantly, we
show that up-regulation of ULBP-2 can be induced by intracellular
as well as virion-associated Vpr leading to an enhanced susceptibil-
ity of cells to NK cell–mediated killing. These data indicate that
Vpr is a key determinant responsible for HIV-1–induced up-
regulation of cell-surface NKG2D ligands and further suggest an
immunomodulatory role for Vpr.
Methods
Antibodies and reagents
Mouse antihuman ULBP-1,-2, -3, MIC-A or -B monoclonal antibodies
(mAbs), soluble NKG2D-IgG Fc fusion proteins and matched IgG Fc
fusion molecules, interfering Abs to NKG2D and matched-IgG control Abs
were obtained from R&D Systems and the fluorochrome-conjugated
secondary Abs from Invitrogen. The anti-p24 (HB-9725) and anti-HA
(12CA5) mAbs were isolated from supernatants of cultured hybridoma
cells obtained from ATCC. The anti-Vpr mouse mAb, 8D1, was a kind gift
of Dr Y. Ishizaka (Research Institute, International Medical Center of Japan,
Tokyo, Japan).4 The Chk2-phospho(Thr68) Abs were obtained from Cell
Signaling, and the H2AX-phospho(Ser139) Abs were from Upstate Biotech-
nology. Phytohemagglutinin-L, aphidicolin (APC), caffeine, and indinavir
were purchased from Sigma-Aldrich, KU55933 from Calbiochem, and the
human recombinant interleukin-2 (rIL-2) from the National Institutes of
Health AIDS Research and Reference Reagent Program.28
Cell lines and isolation of primary cells
HEK 293T and HeLa TZM cells were cultured as described previously.29
CEM.NKR T cells were cultured in RPMI 1640 complete medium (20%
fetal bovine serum, 100 U/mL penicillin, 100 g/mL streptomycin).
Peripheral blood samples were obtained from healthy, HIV-1-seronegative
adult donors who gave written informed consent in accordance with the
Declaration of Helsinki under research protocols approved by the research
ethics review board of the Institut de Recherches Cliniques de Montre´al.
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-
Paque centrifugation as recommended by the manufacturer (GE Health-
care). NK cells and CD4 T lymphocytes were purified from freshly
isolated PBMCs by negative selection using immunomagnetic beads
according to the manufacturer’s instructions (StemCell Technologies). NK
cells were cultured overnight in RPMI 1640 complete medium before use.
CD4 T lymphocytes were activated with phytohemagglutinin-L (5 g/
mL) for 48 hours and then maintained in RPMI 1640 complete medium
supplemented with rIL-2 (100 U/mL).
Plasmids and proviral DNA constructs
The plasmids pSVCMV-VprWT, pSVCMV-HA-VprWT, pSVCMV-Vpr-
R80A, and pSVCMV-IN-VSVg were described previously.15,30 The plas-
mids pSVCMV-VprQ65R and pSVCMV-HA-VprQ65R were generated by
site-directed mutagenesis. The lentiviral vectors pWPI as well as the
packaging plasmid psPAX2 were kindly provided by D. Trono (School of
Life Sciences, Swiss Federal Institute of Technology, Lausanne, Switzer-
land). The lentiviral vector pWPI-VprWT was described previously,15
whereas pWPI-VprR80A and pWPI-VprQ65R were generated using a
similar strategy. The Vpr-, reverse transcriptase-, and integrase-defective
provirus construct HxBruVprRTIN was described previously.31 The
pNL4.3 infectious molecular clone was obtained from the National
Institutes of Health AIDS Research and Reference Reagent Program,32 and
pNL4.3Vpr was generated by insertion of a frameshift mutation in a
unique AflII site. The infectious isogenic CCR5-tropic HxBru.ADA.GFP
and HxBru(Vpr-).ADA.GFP proviruses coexpress Nef and GFP (green
fluorescent protein) from an internal ribosome entry site-containing open
reading frame. The Vpr-defective HxB89LF-PS-R- proviral construct that
contains point mutations in the P6 domain of Gag, which prevent
incorporation of Vpr, was a kind gift from Dr H. Go¨ttlinger (University of
Massachussetts Medical School, Worcester, MA).33
Production of lentiviral vectors and HIV-1 viruses
Lentiviral vectors and HIV-1 infectious viruses were produced and titrated
as described previously.15,29 Noninfectious HIV-1-defective viruses trans-
packaged with VprWT or VprQ65R were produced by transient transfec-
tion of 40 g of provirus construct (NL4.3Vpr or HxBruVprRTIN),
30 g of pSVCMV-VprWT or pSVCMV-VprQ65R, and 12 g of pSVCMV-
IN-VSV-G, in 5  106 HEK 293Tcells using the standard calcium phos-
phate method. To produce defective particles, 100nM of indinavir was
added to the medium 24 hours after transfection. Defective viruses were
titrated by p24 enzyme-linked immunosorbent assay as recommended by
the manufacturer (AIDS and Cancer virus program, National Cancer
Institute-Frederick). To evaluate the packaging efficiency of VprWT and
VprQ65R, virus particles were produced similarly using NL4.3Vpr or
HxBR89LF-PS-R- provirus construct and pSVCMV-HA-VprWT or pS-
VCMV-HA-VprQ65R plasmids.
Lentiviral vector transduction and viral infection
Infection of activated primary CD4 T lymphocytes was performed as
previously described.29 CEM.NKR T cells and primary CD4 T lympho-
cytes were transduced with lentiviral vectors by spinoculation (1200g for
2 hours at 25°C with 8g/mL of polybrene) at a multiplicity of infection
(MOI) of 1.0. Exposure of primary CD4 T lymphocytes to noninfectious
HIV-1 particles was also performed by spinoculation, using equivalent
amounts of viral particles.
Cytotoxicity assay
Infected primary CD4 T-cell targets were prepared by sorting infected GFP-
expressing primary CD4 T cells using an Influx cell sorter (BD Biosciences).
The whole-cell population was used as targets in case of CEM.NKR T cells
transduced with lentiviral vectors or primary CD4 T cells exposed to noninfec-
tious defective particles. NK cells obtained from the same donors who provided
CD4T cells were used for cytotoxicity assay. For some experiments, saturating
concentrations (10g/mL) of NKG2D Abs or matched-IgG control Abs were
added to NK cells or soluble NKG2D-IgG Fc fusion proteins (3g/mL) and
matched IgG Fc fusion molecules were added to target cells for 30 minutes at 4°C
before cytotoxic assay and were maintained throughout the assay. Determination
of NK-cell killing of target cells was done using a standard 4-hour 51Cr release
assay, as described elsewhere.34
Results
HIV-1 up-regulates cell-surface expression of NKG2D ligand
ULBP-2 in primary CD4 T cells in a Vpr-dependent manner
HIV-1 was recently shown to up-regulate the cell-surface expres-
sion of NKG2D ligands, ULBP-1, -2, -3, but not MICA or MICB in
infected primary CD4 T cells.25 To determine whether the Vpr
accessory protein encoded by HIV-1 was playing a role in this
up-regulation, human primary CD4 T cells were infected with
Vpr or Vpr-defective isogenic CCR5-tropic GFP-expressing
HIV-1 virus and cell-surface expression of the NKG2D ligands
were analyzed by flow cytometry 5 days after infection. Basal
expression of NKG2D ligands at the cell-surface of mock-infected
CD4 T lymphocytes was at the limit of detection except for
ULBP2 (Figure 1; and data not shown for MICA and MICB), even
though these ligands could be specifically detected in various
transformed cell lines after treatment of cells with APC, an
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inhibitor of cellular DNA polymerase and a known inducer of
NKG2D ligands22 (supplemental Figure 1, available on the Blood
website; see the Supplemental Materials link at the top of the online
article; and Figure 3). HIV-1 infection consistently induced an
increased expression of ULBP-2 on infected cells (mean fluores-
cence intensity [MFI]  40.65 vs 23.91 for mock), yet this
up-regulation of ULBP-2 was completely abrogated when cells
were infected with Vpr-defective viruses (MFI  23.84; Figure 1).
In contrast, infection of primary CD4 T cells with Vpr or
Vpr-defective virus did not lead to any significant change in the
expression levels of ULBP-1, ULBP-3, MICA, or MICB (Figure 1;
and data not shown) compared with mock-infected cells. Thus,
HIV-1 selectively induces cell-surface expression of the NKG2D
ligand ULBP-2 by a process that is dependent on Vpr.
Vpr enhances the susceptibility of HIV-1–infected CD4
T lymphocytes to NK cell–mediated killing
Because HIV-1 up-regulates cell-surface expression of ULBP-2 in
a Vpr-dependent manner, we next determined whether the presence
of Vpr triggers NK cells to kill infected cells. For this purpose, we
evaluated the ability of nonactivated human primary NK cells to
kill autologous CD4 T lymphocytes infected with Vpr or
Vpr-defective GFP-expressing HIV-1 virus in a 4-hour 51Cr release
assay. As expected, cells infected with WT HIV-1 virus displayed a
marked increase in their susceptibility to NK-cell killing relative to
cells infected with Vpr-defective virus and mock-infected cells
(Figure 2A). The extent of killing of Vpr-defective HIV-1–infected
cells by NK cells was very similar to that of the mock-infected cells
(Figure 2A). Importantly, the increased susceptibility to NK-cell
killing was significantly reduced when the ability of the NKG2D
receptor to bind its ligands was blocked using NKG2D Abs (Figure
2B), thus indicating that the effect of Vpr in triggering NK-cell
killing was mediated in a large part through the NKG2D receptor.
Thus, expression of Vpr during HIV-1 infection of primary CD4
T lymphocytes promotes NK cell–mediated killing at least in part
through the NKG2D receptor.
Expression of Vpr alone is sufficient to increase the expression
of NKG2D ligands
Having shown that HIV-1 up-regulated ULBP-2 expression in a
Vpr-dependent manner, we then evaluated whether the expression
of Vpr, in the absence of any other HIV-1 gene products, was
sufficient to mediate a similar increase in the expression of
ULBP-2. To this end, human primary CD4 T lymphocytes were
transduced with lentiviral vectors that coexpressed Vpr and GFP
Figure 1. CD4 T lymphocytes infected with HIV-1 express ULBP-2 in a Vpr-dependent manner. Human primary CD4 T lymphocytes were mock-infected or infected
with infectious CCR5-tropic HxBru.ADA.GFP or HxBru(Vpr-)ADA.GFP at an MOI of 0.5. After 5 days, mock-infected or GFP-expressing infected CD4 T lymphocytes were
monitored for expression of NKG2D ligands by flow cytometry using specific mAbs directed against ULBP-1, -2, and -3 and appropriate fluorochrome-conjugated secondary
reagents. The histogram with the dashed line represents cells stained with the isotype control Abs; the filled histogram represents mock-infected cells, and the histograms with
the bold and dotted lines represent, respectively, Vpr (HIV WT) and Vpr-defective (HIVVpr) HIV-infected cells, as indicated. MFI values were calculated by subtracting the
corresponding isotype control values. Results shown are representative of the data obtained from 5 different donors.
Figure 2. HIV-1 Vpr enhances the killing of HIV-1–infected CD4 T lymphocytes
by autologous NK cells. Human primary CD4 T lymphocytes were mock-infected
or infected with infectious CCR5-tropic HxBru.ADA.GFP or HxBru(Vpr-)ADA.GFP at
an MOI of 0.5. After 5 days, mock-infected or GFP-expressing infected primary CD4
T lymphocytes were sorted and subsequently exposed to autologous primary NK
cells in a 4-hour 51Cr release assay in the absence (A) or presence (B) of interfering
Abs to NKG2D (-NKG2D) or matched-IgG control Abs (IgG), as indicated. Error bars
represent SEM. Results shown are representative of the data obtained with
3 different donors.
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(WPI-VprWT) or GFP alone (WPI) and GFP-expressing cells were
analyzed for ULBP-2 expression 48 hours after transduction.
Figure 3A reveals that CD4 T lymphocytes transduced with the
Vpr-expressing lentiviral vector displayed an increased expression
of ULBP-2 at the cell surface (MFI  126.9) relative to control
vector-transduced cells (MFI  45.4). To further analyze the effect
of Vpr on the expression of NKG2D ligands and on NK-cell
cytotoxic responses in a more sensitive system, we took advantage
of a natural subclone of a transformed human NK cell–resistant
CD4 T-lymphoblastoid cell line CEM, designated CEM.NKR.
Transduction of CEM.NKR T cells with WPI-VprWT led to a
detectable increase of all tested NKG2D ligands at the cell surface
of GFP cells relative to the WPI control (Figure 3B). Consistent
with the results obtained with infected primary CD4 T cells,
ULBP-2 showed the strongest up-regulation in the presence of Vpr
(MFI  315.8 vs 82.8 for the control). This effect of Vpr on
cell-surface expression of the NKG2D ligands correlated with an
up-regulation of the ligands at the mRNA level (Figure 4).
Similarly, CEM.NKR T cells treated with APC expressed higher
levels of the NKG2D ligands at the cell surface and at the mRNA
level (Figures 3B, 4). Overall, these results indicate that Vpr alone
is sufficient to up-regulate expression of NKG2D ligands.
Up-regulation of NKG2D ligands is dependent on HIV-1
Vpr-mediated activation of the ATR DNA damage/stress
pathway
We and others have recently shown that HIV-1 Vpr engages the
DDB1-CUL4A (VprBP) E3 Ub ligase through a direct association
with the substrate specificity receptor VprBP to induce a cell-cycle
arrest in the G2 phase.15-21 In that context, Vpr mutants that lost the
ability to interact efficiently with the E3 ligase (VprQ65R) or were
presumably unable to associate with putative host-cell substrate(s)
(VprR80A) were found to have a reduced capability to induce a G2
cell-cycle arrest.15 To assess whether Vpr-mediated up-regulation
of NKG2D ligands depended on the ability of the protein to recruit
Figure 3. Up-regulation of cell-surface
NKG2D ligands in cells expressing HIV-1
Vpr. (A) Human primary CD4 T lympho-
cytes were transduced with lentiviral vec-
tors expressing GFP alone (WPI) or coex-
pressing GFP and VprWT (WPI-VprWT).
GFP-expressing cells were monitored for
ULBP-2 cell-surface expression by flow
cytometry 48 hours after transduction us-
ing specific mAbs directed against ULBP-2
and appropriate fluorochrome-conjugated
secondary reagents. (B) CEM.NKR T cells
were transduced with WPI-VprWT or WPI
lentiviral vectors or treated with APC (4M)
as indicated. Cell-surface expression of
NKG2D ligands was monitored on the
GFP-expressing cells 48 hours after trans-
duction or after a 24-hour treatment with
APC, using specific mAbs directed against
ULBP-1, -2, and -3, MICA, MICB, and
appropriate fluorochrome-conjugated sec-
ondary reagents. MFI values were calcu-
lated by subtracting the corresponding iso-
type control values (dashed line). Results
shown are representative of the data ob-
tained from at least 2 independent experi-
ments.
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the DDB1-CUL4A (VprBP) E3 Ub ligase and to promote a G2
cell-cycle arrest, we analyzed the effect of VprR80A and VprQ65R
on cell-surface expression of ULBP-2 because the expression of
this specific NKG2D ligand was found to be consistently up-
regulated by Vpr in all tested cell types. For this purpose,
CEM.NKR T cells were transduced with lentiviral vectors express-
ing GFP alone (WPI) or coexpressing GFP and VprWT (WPI-
VprWT) or Vpr mutants (WPI-VprR80A or WPI-VprQ65R).
Figure 5A (top panel) reveals that, whereas VprWT induced an
up-regulation of ULBP-2 expression compared with the WPI
control (MFI  358.1 vs 118.7), VprR80A and VprQ65R were
drastically attenuated in their ability to induce G2 arrest (supplemen-
tal Figure 2A) and to increase expression of this ligand
(MFI  126.2 and 200.1, respectively), even though their expres-
sion levels were very similar to that of VprWT (Figure 5A bottom
panel). Similar results were also obtained with the VprR80A
mutant in HeLa cells (supplemental Figure 1).
Given that the up-regulation of NKG2D ligands was found to be
dependent on the activation of DNA damage/stress checkpoint
pathway initiated by ATM or ATR,22 we next sought to test whether
Vpr-mediated up-regulation of NKG2D ligands relied on its ability
to activate the ATR DNA damage/stress pathway. To this end,
CEM.NKR T cells were transduced with WPI or WPI-VprWT
lentiviral vectors in the presence or absence of caffeine, an inhibitor
of ATR and ATM previously reported to prevent Vpr-mediated G2
cell-cycle arrest.14 Results from these experiments revealed that
caffeine treatment not only inhibited Vpr-mediated G2 cell-cycle
arrest (supplemental Figure 2B) but also significantly reduced
cell-surface up-regulation of ULBP-2 (Figure 5B). Similarly,
induction of ULBP-2 by APC, a known activator of DNA damage
checkpoints,22 was drastically diminished in the presence of
caffeine (Figure 5B). Equivalent results were obtained in HeLa
cells (data not shown). To exclude the involvement of ATM, we
evaluated the effect of the specific ATM inhibitor KU5593335 on
Vpr-induced up-regulation of ULBP-2. We found that treatment of
transduced cells with KU55933 had no effect on Vpr-mediated G2
cell-cycle arrest (supplemental Figure 2C) and up-regulation of
ULBP-2 (Figure 5C). Comparable results were also obtained in
HeLa cells (data not shown). In contrast, KU55933 affected
APC-induced ULBP-2 up-regulation (Figure 5C) and prevented
phosphorylation of 2 known targets of ATM, Chk2 and H2AX after
 irradiation (Figure 5D). Taken together, these results suggest that
Vpr up-regulates cell-surface expression of NKG2D ligands by a
process that depends on the recruitment of the DDB1-CUL4A
(VprBP) E3 ligase and on the activation of the ATR-mediated DNA
damage/stress checkpoint.
Vpr-mediated up-regulation of NKG2D ligands triggers
NK-cell–mediated killing
Given that expression of Vpr alone is sufficient to up-regulate
expression of NKG2D ligands in CEM.NKR T cells, we next
determined whether Vpr-expressing cells are more sensitive to
NK cell–mediated killing. To this end, we analyzed the susceptibil-
ity of the entire population of lentiviral vector-transduced
CEM.NKR T cells to NK cell–mediated killing, 48 hours after
transduction, in a 4-hour 51Cr release assay. Figure 6A shows that
CEM.NKR T cells transduced with Vpr-expressing lentiviral vec-
tors displayed a remarkable sensitivity to NK cell–mediated killing
compared to the control vector-transduced cells. Importantly, the
enhanced NK-cell–mediated lysis of Vpr-expressing cells was
completely abrogated when binding of NKG2D ligands to the
NKG2D receptor was blocked using soluble NKG2D-IgG Fc
fusion proteins, providing additional evidence that the NK-cell
cytotoxic response triggered by Vpr occurred via expression of
NKG2D ligands. Furthermore, as expected, the G2 arrest-defective
mutant, VprR80A, which fails to efficiently up-regulate NKG2D
ligands, was unable to trigger NK cell–mediated killing at levels
comparable to those induced by VprWT (Figure 6B). Interestingly,
although we obtained a transduction efficiency of approximately
30% (data not shown), the extent of NK cell–mediated killing
induced by Vpr was very similar to that observed with APC
treatment when using NK cells from the same donor (compare
Figure 6A with Figure 6C). These results raised the possibility that
Vpr may be acting beyond transduced cells in this experimental
setting. Indeed, an analysis of GFP and GFP	 cells within the
WPI-VprWT-treated cell population revealed that ULBP-2 cell-
surface expression was up-regulated in both cell populations
relative to the WPI control lentiviral vector (Figure 6D). However,
although Vpr-mediated up-regulation of ULBP-2 was stable in
GFP cells over a 96-hour period after transduction, it occurred in a
transient manner in GFP	 cells, thus suggesting that the effect in
GFP	 cells may be mediated by delivery of virion-associated Vpr
rather than expression of the transgene (data not shown). Taken
together, these results indicate that expression of Vpr is sufficient to
trigger NK cell–mediated killing through an increased expression
of NKG2D ligands.
Delivery of virion-associated Vpr via defective HIV-1 particles
up-regulates ULBP-2 expression and triggers NK cell–mediated
killing
We and others have previously shown that virion-associated Vpr
could trigger G2 cell-cycle arrest in transformed or primary T cells
by a process that was insensitive to antiretroviral agents.9,10
Therefore, we next examined whether delivery of virion-associated
Vpr by defective HIV-1 particles could up-regulate NKG2D
ligands. To mimic infection by defective viruses, we infected
primary CD4 T lymphocytes with HIV-1 particles that are unable
to express any HIV-1 proteins de novo but contain virion-
associated Vpr. First, HIV-1 particles trans-packaged with VprWT
Figure 4. Augmentation of NKG2D ligand mRNA expression in CEM.NKR T cells
expressing HIV-1 Vpr. CEM.NKR T cells were transduced with lentiviral vectors
expressing GFP alone (WPI) or coexpressing GFP and VprWT (WPI-VprWT). GFP
cells were sorted for analysis 48 hours after transduction. Alternatively, transduced
cells were treated (or not) with 4M APC for 24 hours. DNase-treated RNA was
analyzed for NKG2D ligand expression by real-time reverse-transcriptase polymer-
ase chain reaction. Target gene expression in Vpr-transduced and APC-treated
CEM.NKR T cells was normalized for glyceraldehyde 3-phosphate dehydrogenase
and hypoxanthine-guanine phosphoribosyltransferase (HPRT) expression, and the
data were subsequently expressed as a fold increase relative to WPI-transduced or
untreated cells, respectively. Results shown represent a mean fold increase. Error
bars represent SEM. Results are representative of the data obtained from 4 indepen-
dent experiments.
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or VprQ65R were produced in the presence of the protease
inhibitor indinavir to make them defective for infection. In this
context, indinavir-treated viruses were found to be noninfectious
but still able to deliver virion-associated Vpr.9,10 These indinavir-
treated viruses were unable to establish productive infection as
evaluated by infection of HeLa TZM (data not shown). Neverthe-
less, noninfectious HIV-1 particles trans-packaged with VprWT
were still capable of inducing an up-regulation of ULBP-2
cell-surface expression in primary CD4 T lymphocytes compared
to isogenic noninfectious virus trans-packaged with VprQ65R
(Figure 7A). Notably, the VprQ65R mutant was found to be
packaged into viral particles in quantities comparable to VprWT
(Figure 7B), thus excluding the possibility that the lack of ULBP-2
up-regulation observed with this mutant was the result of ineffi-
cient packaging. As a negative control, we used a proviral construct
(LF/PS) containing mutations in the P6 domain of Gag, which
prevent the incorporation of Vpr (Figure 7B). Similar results were
also obtained with naturally noninfectious viral particles produced
from a well-characterized reverse transcriptase and integrase-
defective proviral construct (HxBruVprRTIN)31 that was
trans-packaged with VprWT or VprQ65R (Figure 7C). Importantly,
primary CD4T lymphocytes exposed to indinavir-treated VprWT-
containing HIV-1–defective particles were more susceptible to
autologous NK-cell–mediated killing than cells exposed to HIV-1–
Figure 5. Vpr-mediated up-regulation of ULBP2 requires the recruitment of the DDB1-CUL4A (VprBP) E3 ligase complex and activation of the DNA damage/stress
checkpoint arrest initiated by ATR. (A) CEM.NKR T cells were transduced with lentiviral vectors expressing GFP alone (WPI) or coexpressing GFP and VprWT (WPI-VprWT)
or Vpr mutants (WPI-VprR80A or WPI-VprQ65R), as indicated. At 48 hours after transduction, GFP-expressing cells were monitored for ULBP-2 cell-surface expression by
flow cytometry using specific mAbs directed against ULBP-2 and appropriate fluorochrome-conjugated secondary reagents (top panel). Expression of VprWT and Vpr mutants
(VprR80A and VprQ65R) was evaluated by intracellular staining and flow cytometry using anti-Vpr mAbs and appropriate fluorochrome-conjugated secondary reagents
(bottom panel). (B-C) CEM.NKR T cells were transduced with lentiviral vectors WPI or WPI-VprWT or treated with APC (4M), in the presence or absence of caffeine (2.5mM)
(B) and in the presence of DMSO or KU55933 (10M) (C) as indicated. Cell-surface expression of ULBP-2 was monitored on GFP-expressing cells 48 hours after transduction
or on the total cell population after a 24-hour treatment with APC. MFI values were calculated by subtracting the corresponding isotype control values (dashed line). Results
shown are representative of the data obtained from at least 2 independent experiments. (D) HeLa cells were irradiated with  rays (10 Gy from a Cs137 source) in the presence
of DMSO or KU55933 (10M). Cells were then lysed and sonicated 1 hour after irradiation, and phosphorylation of Chk2 and H2AX was monitored by Western blotting using
specific Abs.
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Figure 6. Vpr-mediated up-regulation of
NKG2D ligands in target cells promotes
NK cell–mediated killing. (A) CEM.NKR
T cells were transduced with lentiviral vectors
WPI or WPI-VprWT and then exposed to pri-
mary NK cells in a 4-hour 51Cr release assay
48 hours after transduction, in the presence of
soluble NKG2D-IgG Fc fusion proteins or
matched-IgG Fc fusion molecules, as indi-
cated. (B) CEM.NKR T cells were transduced
with lentiviral vectors WPI-VprWT or WPI-
VprR80A and then assessed for cell lysis by
primary NK cells in a 51Cr release assay
48 hours after transduction. (C) CEM.NKR
T cells were treated or not with APC (4M) and
analyzed, as in panel A, 24 hours after treat-
ment. Primary NK cells used in panels A and C
were isolated from the same donor. Error bars
represent SEM. (D) Cell-surface expression of
ULBP-2 was monitored on GFP and GFP	
CEM.NKR T cells 48 hours after transduction
with lentiviral vectors expressing GFP alone
(WPI) or coexpressing GFP and VprWT (WPI-
VprWT) as indicated. MFI values were calcu-
lated by subtracting the corresponding isotype
control values (dashed line). Results shown
are representative of the data obtained from at
least 2 independent experiments.
Figure 7. Virion-associated Vpr up-regulates ULBP-2 expression in noninfected target cells and triggers NK cell–mediated killing. (A) Human primary CD4
T lymphocytes were exposed to indinavir-treated noninfectious viral particles that were trans-packaged with VprWT or the VprQ65R mutant, as indicated, and cell-surface
expression of ULBP-2 was monitored 24 hours after exposure using specific mAbs directed against ULBP-2 and appropriate fluorochrome-conjugated secondary reagents.
(B) HIV-1Vpr and HIV-1Vpr LF/PS viruses (P6-mutated Gag-encoding virus that does not incorporate Vpr) trans-packaged with HA-tagged VprWT or VprQ65R were
produced as described in “Production of lentiviral vectors and HIV-1 viruses.” Virion-associated HA-tagged VprWT and VprQ65R were detected by Western blotting using
anti-HA mAbs. (C) Primary CD4 T lymphocytes were exposed to reverse transcriptase- and integrase-defective (HIVVprRTIN) viral particles that were trans-packaged
with VprWT or the VprQ65R mutant as indicated, and cell-surface expression of ULBP-2 was monitored 24 hours after exposure. MFI values were calculated by subtracting the
corresponding isotype-control values (dashed line). (D) Primary CD4 T lymphocytes exposed to indinavir-treated noninfectious viral particles containing VprWT or VprQ65R
were added 24 hours after exposure to autologous primary NK cells in a 4-hour 51Cr release assay, as indicated. Error bars represent SEM. Results shown are representative of
the data obtained from 2 independent donors.
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defective particles containing the VprQ65R mutant (Figure 7D).
Overall, these results suggest that delivery of virion-associated Vpr
protein through HIV-1–defective particles can up-regulate cell-
surface expression of NKG2D ligands in noninfected cells and as a
result can trigger NK-cell cytotoxic responses.
Discussion
HIV-1 infection of primary CD4 T cells up-regulates cell-surface
expression of specific ligands for the activating NKG2D receptor,
including ULBP-1, -2, and -3, but not MICA or MICB.25,26 This
up-regulation was also found to occur in vivo because NKG2D
ligands were expressed at high levels on endogenously HIV-1–
infected CD4 T cells.27 In particular, ULBP molecules (especially
ULBP-2) were clearly expressed on p24 cells, whereas the levels
of MICA and MICB were almost undetectable. However, the
identity of the viral factor(s) involved in NKG2D ligands expres-
sion has remained undefined. We demonstrated in this study that
the HIV-1 Vpr accessory protein is responsible for increasing
expression of these ligands, which are important in triggering
NK-cell responses on infected cells. In particular, we observed that
primary CD4 T cells responded to HIV-1 infection by selectively
augmenting cell-surface expression of ULBP-2 in a Vpr-dependent
manner (Figure 1). Furthermore, expression of Vpr alone was
sufficient to enhance ULBP-2 expression in human CD4 T lym-
phocytes (Figure 3A). Our results showing a lack of MICA and
MICB cell-surface up-regulation by HIV-1 concur with recent
reports.25-27 However, in contrast to the study of Ward et al,25 we
did not detect any significant up-regulation of ULBP-1 and
ULBP-3 in HIV-infected cells relative to uninfected cells. Interest-
ingly, CEM.NKR T cells expressing solely Vpr showed an up-
regulation of all tested NKG2D ligands, with the strongest effect
observed with ULBP-2 (Figure 3B). Aside from the implication
that HIV replication and expression of other virus proteins are not
required for this activity of Vpr, this latter finding suggests that,
perhaps in the context of a replicating virus, another viral function
may limit the cell-surface expression of some NKG2D ligands. In
this regard, recent evidence suggests that the HIV-1 Nef accessory
protein down-regulates the cell-surface expression of NKG2D
ligands as a means to evade NK-cell recognition.26 This activity of
Nef may explain why Vpr-mediated up-regulation of NKG2D
ligands is selective in the context of HIV-1 infection where Nef is
expressed compared to cells that only express Vpr. In addition, it
may also account for the discrepancies observed between our
results and those of Ward et al25 because different Nef variants were
found to down-regulate NKG2D ligands selectively and with
different efficiencies.26 However, we cannot exclude the possibility
that differences in viral strain and MOI may explain these
discrepancies. Importantly, despite the presence of Nef, HIV
infection, in a Vpr-dependent manner, increased the cell-surface
expression of ULBP-2 in infected primary cells and triggered
NK cell–mediated killing, at least in part, via the NKG2D receptor
(Figure 2). Studying the regulation of NKG2D ligand expression
by Vpr and other viral products, including Nef, should help
understand how these ligands are modulated during HIV-1 infection.
Our results suggest that Vpr increases NKG2D ligand expres-
sion by a process that relies on the engagement of the DDB1-
CUL4A (VprBP) E3 Ub ligase complex and on the activation of the
ATR-mediated DNA damage checkpoint (Figure 5). Specifically,
mutants of Vpr that were unable to induce a G2 cell-cycle arrest,
either because they lost the ability to interact efficiently with the E3
ligase or were presumably unable to target putative host-cell
substrate(s) for polyubiquitination and degradation,15 were found
to have a reduced capability in up-regulating NKG2D ligand
expression (Figure 5A). A role of ATR in this activity of Vpr was
supported by experiments, which demonstrated that Vpr-mediated
ULBP-2 up-regulation was efficiently blocked by caffeine, an
inhibitor of ATR and ATM, but not by the ATM inhibitor KU55933
(Figure 5B-C). In contrast, ligand augmentation in response to
APC, a known activator of DNA damage pathways,22 was inhibited
by both inhibitors (Figure 5B-C). Our findings are consistent with
earlier evidence showing that expression of NKG2D ligands is
up-regulated by activation of the DNA damage/stress pathways
initiated by ATR or ATM22 and that Vpr activates specifically the
ATR-mediated DNA damage pathway.14
Our results support a model where virion-associated Vpr
could also up-regulate NKG2D ligands after its delivery into
target cells and, as a result, would trigger NK-cell cytotoxic
responses (Figure 7). Studies have revealed that the ratio of
defective to infectious viral particles may be relatively high.
These defective viral particles, which are estimated to be in the
range of 8 to 20 to 1, still contain packaged Vpr and therefore
could induce expression of NKG2D ligands at the cell surface of
noninfected CD4 T cells and promote their killing by NK cells
via NKG2D. These Vpr-containing defective particles may
explain some of the bystander killing observed in acute HIV-1
and simian immunodeficiency virus infections when, for in-
stance, more than 50% of CD4 T cells in the gastrointestinal
lamina propria are depleted,36-38 and yet only 7% of gastrointes-
tinal CD4 T cells are found to be infected.37
HIV-1 appears to have developed several strategies to offset
the capability of activating NK cells efficiently. The selective
preservation of cell-surface expression of HLA-C and -E
molecules39 and the down-modulation of NKG2D ligands26 and
ligands for the NTB-A (NK-T-B cell antigen) and 2B4 (CD244)
activating coreceptors25 by Nef represent strategies used by
HIV-1 virus to blunt NK-cell recognition. Nevertheless, HIV-1,
through Vpr, still enhances the expression of some NKG2D
ligands and triggers nonactivated NK cells to kill HIV-1–
infected cells. A role of Vpr in increasing expression of NKG2D
ligands and promoting NK-cell cytotoxic responses would seem
at first counterproductive to the virus because it would make the
infected cells more potent targets for NK cells. However, Vpr
provides the virus with a selective replication and propagation
advantage because it promotes infection of monocyte-derived
macrophages,40,41 a cell type that is refractory to ATR activation
by Vpr13 and consequently would not be expected to express
ligands for the activating NKG2D receptor during infection.
Furthermore, this activity of Vpr on modulating NKG2D ligand
expression may not only contribute to HIV-1–induced CD4
T-cell depletion but may also play a role in the perturbation of
NK-cell functions observed during HIV infection. Increasing
evidence indicates that NK-cell function as a whole is compro-
mised during HIV infection through poorly understood mecha-
nisms. HIV infection is associated with significant changes in
NK-cell subset distribution in the peripheral circulation that are
partially attributable to the emergence of a novel subset of NK
cells that is rare in healthy persons, the CD3	 CD56	 CD16
NK cells. These cells not only lack the majority of NK-cell
effector functions, including killing, cytokine secretion, and
antibody-dependent cellular cytotoxicity, but also exhibit aber-
rant dendritic cell editing.42-44 The observation that the redistri-
bution of NK cells toward this anergic subset of cells is directly
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correlated with viral load suggests that the presence of viral
antigens has a role in NK-cell dysfunction. Indeed, in viremic
patients, NK cells display several phenotypic and functional
alterations,27 including a slightly decreased expression of the
NKG2D receptor,43 although no significant alteration in the
percentage of NKG2D cells was observed.27 Interestingly,
down-regulation of NKG2D also occurs in some cancer patients
as a consequence of a soluble form of MICA released by tumor
cells on proteolytic cleavage.45,46 Furthermore, sustained local-
ized expression of ligands for the activating NKG2D receptor
was reported to down-regulate NKG2D and to impair NK-cell
cytotoxic activity in vitro and in mouse models, thus reducing
tumor immunosurveillance.47,48 Hence, chronic exposure to
NKG2D ligand-expressing tumor cells or to soluble NKG2D
ligands shedded by tumor cells induces alteration of NKG2D
function in NK cells.48,49 By analogy, the activity of Vpr on
NKG2D ligands could contribute to NK-cell dysfunction be-
cause of sustained effector activation, thus effectively promot-
ing viral immune evasion. A role of Vpr in HIV-1–induced
NK-cell dysfunction is consistent with recent data, which
showed that NK cells derived from human PBMCs infected in
vitro with HIV-1 Vpr virus or exposed to recombinant Vpr
protein exhibited reduced target-cell killing and reduced produc-
tion of -interferon compared with their Vpr	 counterparts.50
This NK-cell defect was not the result of direct infection of NK
cells but rather resulted in part from the presence of membrane-
associated factors on infected or recombinant Vpr-exposed
nonmyeloid target cells. Hence, assessing whether the activity
of Vpr on NKG2D ligands desensitizes the NKG2D receptor and
evades NKG2D-mediated immune surveillance will further
improve our understanding of the immune evasive strategies
used by HIV to disarm innate immune responses and will help in
the development of immunotherapeutic options for HIV-1–
infected persons.
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